Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$6.7 million.

  • Cartesian Therapeutics' Change in Accured Expenses fell 172.97% to -$432,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year increase of 61.40%. This contributed to the annual value of -$6.7 million for FY2024, which is 144.15% down from last year.
  • As of FY2024, Cartesian Therapeutics' Change in Accured Expenses stood at -$6.7 million, which was down 144.15% from -$2.8 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Change in Accured Expenses ranged from a high of $2.2 million in FY2022 and a low of -$6.7 million during FY2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$2.8 million (2023), whereas its average is -$2.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 138.43% in 2021, then tumbled by 224.82% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Change in Accured Expenses stood at -$2.8 million in 2020, then surged by 138.43% to $1.1 million in 2021, then surged by 108.48% to $2.2 million in 2022, then slumped by 224.82% to -$2.8 million in 2023, then plummeted by 144.15% to -$6.7 million in 2024.